{
  "abstract": "Background: The platelet-to-hemoglobin ratio (PHR) is a proposed prognostic marker in cardiovascular disease, but it has not been evaluated against a broad major adverse cardiovascular events (MACE) endpoint in a dedicated percutaneous coronary intervention (PCI) cohort, and whether it adequately summarizes its two components remains untested.\n\nMethods: We analyzed 1,551 patients pooled from two prospective Korean drug-eluting stent registries (2016–2022). The PHR was calculated as platelet count (×10⁹/L) divided by hemoglobin (g/L). The primary endpoint was 1-year MACE, with follow-up censored at 365 days, a composite of all-cause death, myocardial infarction, stroke, repeat revascularization, or heart failure hospitalization. Multivariable Cox models included eight prespecified clinical covariates; the functional form was examined with restricted cubic splines, and the PHR was decomposed using nested models and a log-scale ratio-constraint test.\n\nResults: MACE occurred in 107 patients (6.9%) within 1 year. A higher PHR was independently associated with MACE (adjusted hazard ratio [HR] per 1-standard deviation, 1.21; 95% confidence interval [CI], 1.05–1.40; P = 0.008), with no evidence of nonlinearity ( P = 0.700). Adding the PHR improved the clinical model (likelihood-ratio P = 0.013); the ratio constraint was not rejected ( P = 0.765), and a single log-PHR term retained 98.7% of the two-component likelihood-ratio χ ² increment over the clinical model in this cohort (bootstrap 95% CI, 21.8%–100%). The PHR was associated with all-cause and cardiovascular death (both HR, 1.28), paralleling hemoglobin. Repeat revascularization was associated with platelet count (HR, 1.39; P = 0.014), but not significantly with PHR (HR, 1.24; P = 0.081). Risk was concentrated in patients with both anemia and a platelet count at or above the median (adjusted HR, 1.82; 95% CI, 1.05–3.15). The gain in discrimination was negligible ( Δ AUC, +0.003; 95% CI, −0.003 to +0.012), and net benefit was virtually unchanged.\n\nConclusions: The admission PHR was independently associated with 1-year MACE after PCI, with no evidence of nonlinearity, and its log-scale component effects were compatible with the ratio constraint in this cohort. Given the negligible gain in discrimination and net benefit, the PHR is an independent prognostic marker rather than a tool for risk reclassification.\n\nRegistry registration: Clinical Research Information Service KCT0003392 and KCT0005008.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital , ,"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Jeong Tae Byoun"
    },
    {
      "affs": [
        0
      ],
      "name": "Donghyeon Joo"
    },
    {
      "affs": [
        0
      ],
      "name": "Sungho Jo"
    },
    {
      "affs": [
        0
      ],
      "name": "Jae Young Cho"
    },
    {
      "affs": [
        0
      ],
      "name": "Kyeong Ho Yun"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/fcf0ydnsrcn19.bib",
  "cited_by": 0,
  "doi": "10.3389/fcvm.2026.1981126",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690651/?tool=EBI",
  "id": "fcf0ydnsrcn19",
  "issns": [
    "2297-055X"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13690651",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|Inflammatory Biomarkers in Disease Prognosis"
    ]
  ],
  "openalex": "W7221085106",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690651/pdf/?tool=EBI",
  "pmcid": "PMC13690651",
  "pmid": null,
  "published": "2026-10-09",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/fcf0ydnsrcn19.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:59Z",
      "native_id": "PMC:PMC13690651",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13690651"
    },
    {
      "first_seen": "2026-10-30T12:20:10Z",
      "native_id": "10.3389/fcvm.2026.1981126",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fcvm.2026.1981126/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Inflammatory Biomarkers in Disease Prognosis",
      "subfield": "oncology"
    }
  ],
  "title": "Admission platelet-to-hemoglobin ratio and 1-year outcomes after percutaneous coronary intervention: a multicenter registry cohort study",
  "title_text": "Admission platelet-to-hemoglobin ratio and 1-year outcomes after percutaneous coronary intervention: a multicenter registry cohort study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:10Z",
  "url": "https://research.draconitic.com/paper/fcf0ydnsrcn19",
  "venue": "Frontiers in cardiovascular medicine",
  "versions": []
}